The BMPR1B antibody targets Bone Morphogenetic Protein Receptor Type 1B, a transmembrane serine/threonine kinase receptor part of the TGF-β superfamily. BMPR1B plays a critical role in mediating cellular responses to BMP ligands (e.g., BMP2. BMP4), regulating processes like cell differentiation, proliferation, apoptosis, and tissue development. It forms complexes with type II BMP receptors, activating SMAD-dependent signaling pathways and influencing embryogenesis, skeletal development, and reproductive system function. Dysregulation of BMPR1B is linked to diseases, including cancers (e.g., breast, ovarian), pulmonary arterial hypertension, and skeletal disorders.
BMPR1B antibodies are essential tools for detecting receptor expression and localization in research applications such as Western blotting, immunohistochemistry, and flow cytometry. They help elucidate BMPR1B's role in signaling pathways, disease mechanisms, and potential therapeutic targeting. Commercial antibodies are typically validated for specificity against human, mouse, or rat BMPR1B, often targeting epitopes in the extracellular or intracellular kinase domains. Researchers use these antibodies to study BMPR1B's interaction with ligands, downstream effectors, and its crosstalk with other pathways, such as Wnt or FGF, in developmental and pathological contexts.